Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Update

Entera Bio Ltd. (NASDAQ:ENTX) was the recipient of a significant increase in short interest during the month of November. As of November 30th, there was short interest totalling 63,000 shares, an increase of 19.8% from the November 15th total of 52,600 shares. Based on an average trading volume of 66,800 shares, the short-interest ratio is currently 0.9 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Entera Bio in a research report on Monday, November 11th.

Hedge Funds Weigh In On Entera Bio

A hedge fund recently bought a new stake in Entera Bio stock. Signature Estate & Investment Advisors LLC acquired a new position in Entera Bio Ltd. (NASDAQ:ENTX) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 47,328 shares of the company’s stock, valued at approximately $90,000. Signature Estate & Investment Advisors LLC owned 0.13% of Entera Bio at the end of the most recent reporting period. Institutional investors and hedge funds own 14.11% of the company’s stock.

Entera Bio Trading Down 1.8 %

Shares of ENTX opened at $2.16 on Monday. The business’s 50 day moving average is $1.80 and its 200 day moving average is $1.83. The company has a market capitalization of $77.28 million, a PE ratio of -8.31 and a beta of 1.55. Entera Bio has a 12-month low of $0.52 and a 12-month high of $3.35.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.